Back

BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.

29 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Basic Science - Therapeutic approach Cell Signalling HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Professor Angela Clerk

University of Reading, Reading (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Cardiac gene therapy with phosphodiesterases PDE2A and PDE4B in a mouse model of heart failure
Mr J. Margaria (Turin, IT)
Abstract
Presentation thumbnail
Acute and subacute functional effects of relaxin-2 on human mammary artery
Doctor F. Vasques-Novoa (Porto, PT)
Abstract
Presentation thumbnail
Microencapsulated insulin-like growth factor 1 improves cardiac function after experimental myocardial infarction in comparison to low-dose mesenchymal stem cells
Doctor C. Baez Diaz (Madrid Caceres, ES)
Abstract
Presentation thumbnail
Pharmacological activation of sphingosine 1-phosphate receptor 1 (S1pr1) enhances arteriole formation and improves cardiac function after myocardial infarction (MI)
Professor L. Zhang (Shanghai, CN)
Abstract
Presentation thumbnail
Raf kinase inhibitor protein regulates fibrosis depending on myocardial oxidative stress
Doctor A. Kazakov (Homburg, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - Basic Science - Therapeutic approach

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources